VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 14.9% in March

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a significant drop in short interest in March. As of March 13th, there was short interest totaling 1,293,080 shares, a drop of 14.9% from the February 26th total of 1,519,296 shares. Based on an average daily volume of 535,758 shares, the days-to-cover ratio is currently 2.4 days. Currently, 3.4% of the company’s stock are short sold.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.57 on Wednesday. VistaGen Therapeutics has a 1 year low of $0.43 and a 1 year high of $5.14. The company has a market capitalization of $22.64 million, a P/E ratio of -0.30 and a beta of 0.29. The company’s fifty day moving average is $0.59 and its two-hundred day moving average is $2.22.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.14 million. As a group, equities analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Analyst Ratings Changes

VTGN has been the subject of several recent analyst reports. Jefferies Financial Group restated a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Wall Street Zen cut shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $0.95.

Institutional Trading of VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTGN. Seven Fleet Capital Management LP acquired a new stake in VistaGen Therapeutics during the 4th quarter worth approximately $42,000. Virtu Financial LLC acquired a new position in shares of VistaGen Therapeutics in the fourth quarter valued at approximately $25,000. Tudor Investment Corp ET AL purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter worth approximately $50,000. Millennium Management LLC raised its stake in shares of VistaGen Therapeutics by 853.0% during the fourth quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after purchasing an additional 176,369 shares during the last quarter. Finally, Luminus Management LLC acquired a new stake in shares of VistaGen Therapeutics during the fourth quarter worth $232,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.